Maria Cristina Grò
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maria Cristina Grò has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Caterina Ambrosio
National Center for Drug Research and Evaluation, National Institute of Health, 00161 Rome, Italy
4 shared publications Colomba Giorgi
Laboratory of Virology, Istituto Superiore di Sanità, Rome, Italy
3 shared publications- Luisa Accardi
Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy
3 shared publications - Paola Di Bonito
Department of Infectious Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
3 shared publications - Tommaso Costa
Department of Pharmacology, Istituto Superiore di Sanità, Rome, Italy
3 shared publications - Paola Molinari
National Center for Drug Research and Evaluation, National Institute of Health, 00161 Rome, Italy
2 shared publications
Latest Publications
- Open Access
- 14 March 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , srep44247
Systematic errors in detecting biased agonism: Analysis of current methods and development of a new model-free approach
Discovering biased agonists requires a method that can reliably distinguish the bias in signalling due to unbalanced activation of diverse transduction proteins from that of differential amplification inherent to the system being studied, which invariably results from the non-linear nature of biological signalling networks and their measurement. We have systematically compared the performance of seven methods of bias diagnostics, all of which are based on the analysis of concentration-response curves of ligands according to classical receptor theory. We computed bias factors for a number of β-adrenergic agonists by comparing BRET assays of receptor-transducer interactions with Gs, Gi and arrestin. Using the same ligands, we also compared responses at signalling steps originated from the same receptor-transducer interaction, among which no biased efficacy is theoretically possible. In either case, we found a high level of false positive results and a general lack of correlation among methods. Altogether this analysis shows that all tested methods, including some of the most widely used in the literature, fail to distinguish true ligand bias from “system bias” with confidence. We also propose two novel semi quantitative methods of bias diagnostics that appear to be more robust and reliable than currently available strategies.
- 14 March 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , srep44247
Open AccessSystematic errors in detecting biased agonism: Analysis of current methods and development of a new model-free approach
Discovering biased agonists requires a method that can reliably distinguish the bias in signalling due to unbalanced activation of diverse transduction proteins from that of differential amplification inherent to the system being studied, which invariably results from the non-linear nature of biological signalling networks and their measurement. We have systematically compared the performance of seven methods of bias diagnostics, all of which are based on the analysis of concentration-response curves of ligands according to classical receptor theory. We computed bias factors for a number of β-adrenergic agonists by comparing BRET assays of receptor-transducer interactions with Gs, Gi and arrestin. Using the same ligands, we also compared responses at signalling steps originated from the same receptor-transducer interaction, among which no biased efficacy is theoretically possible. In either case, we found a high level of false positive results and a general lack of correlation among methods. Altogether this analysis shows that all tested methods, including some of the most widely used in the literature, fail to distinguish true ligand bias from “system bias” with confidence. We also propose two novel semi quantitative methods of bias diagnostics that appear to be more robust and reliable than currently available strategies.
- Open Access
- 6 August 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (8) , e0132865
Pharmacological Profile of Nociceptin/Orphanin FQ Receptors Interacting with G-Proteins and β-Arrestins 2
Nociceptin/orphanin FQ (N/OFQ) controls several biological functions by selectively activating an opioid like receptor named N/OFQ peptide receptor (NOP). Biased agonism is emerging as an important and therapeutically relevant pharmacological concept in the field of G protein coupled receptors including opioids. To evaluate the relevance of this phenomenon in the NOP receptor, we used a bioluminescence resonance energy transfer technology to measure the interactions of the NOP receptor with either G proteins or β-arrestin 2 in the absence and in presence of increasing concentration of ligands. A large panel of receptor ligands was investigated by comparing their ability to promote or block NOP/G protein and NOP/arrestin interactions. In this study we report a systematic analysis of the functional selectivity of NOP receptor ligands. NOP/G protein interactions (investigated in cell membranes) allowed a precise estimation of both ligand potency and efficacy yielding data highly consistent with the known pharmacological profile of this receptor. The same panel of ligands displayed marked differences in the ability to promote NOP/β-arrestin 2 interactions (evaluated in whole cells). In particular, full agonists displayed a general lower potency and for some ligands an inverted rank order of potency was noted. Most partial agonists behaved as pure competitive antagonists of receptor/arrestin interaction. Antagonists displayed similar values of potency for NOP/Gβ1 or NOP/β-arrestin 2 interaction. Using N/OFQ as reference ligand we computed the bias factors of NOP ligands and a number of agonists with greater efficacy at G protein coupling were identified.
- 6 August 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (8) , e0132865
Open AccessPharmacological Profile of Nociceptin/Orphanin FQ Receptors Interacting with G-Proteins and β-Arrestins 2
Nociceptin/orphanin FQ (N/OFQ) controls several biological functions by selectively activating an opioid like receptor named N/OFQ peptide receptor (NOP). Biased agonism is emerging as an important and therapeutically relevant pharmacological concept in the field of G protein coupled receptors including opioids. To evaluate the relevance of this phenomenon in the NOP receptor, we used a bioluminescence resonance energy transfer technology to measure the interactions of the NOP receptor with either G proteins or β-arrestin 2 in the absence and in presence of increasing concentration of ligands. A large panel of receptor ligands was investigated by comparing their ability to promote or block NOP/G protein and NOP/arrestin interactions. In this study we report a systematic analysis of the functional selectivity of NOP receptor ligands. NOP/G protein interactions (investigated in cell membranes) allowed a precise estimation of both ligand potency and efficacy yielding data highly consistent with the known pharmacological profile of this receptor. The same panel of ligands displayed marked differences in the ability to promote NOP/β-arrestin 2 interactions (evaluated in whole cells). In particular, full agonists displayed a general lower potency and for some ligands an inverted rank order of potency was noted. Most partial agonists behaved as pure competitive antagonists of receptor/arrestin interaction. Antagonists displayed similar values of potency for NOP/Gβ1 or NOP/β-arrestin 2 interaction. Using N/OFQ as reference ligand we computed the bias factors of NOP ligands and a number of agonists with greater efficacy at G protein coupling were identified.
- 27 July 2011
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 438 (1) , 191-202
Divergent agonist selectivity in activating β1- and β2-adrenoceptors for G-protein and arrestin coupling
The functional selectivity of adrenergic ligands for activation of β1- and β2-AR (adrenoceptor) subtypes has been extensively studied in cAMP signalling. Much less is known about ligand selectivity for arrestin-mediated signalling pathways. In the present study we used resonance energy transfer methods to compare the ability of β1- and β2-ARs to form a complex with the G-protein β-subunit or β-arrestin-2 in response to a variety of agonists with various degrees of efficacy. The profiles of β1-/β2-AR selectivity of the ligands for the two receptor–transducer interactions were sharply different. For G-protein coupling, the majority of ligands were more effective in activating the β2-AR, whereas for arrestin coupling the relationship was reversed. These data indicate that the β1-AR interacts more efficiently than β2-AR with arrestin, but less efficiently than β2-AR with G-protein. A group of ligands exhibited β1-AR-selective efficacy in driving the coupling to arrestin. Dobutamine, a member of this group, had 70% of the adrenaline (epinephrine) effect on arrestin via β1-AR, but acted as a competitive antagonist of adrenaline via β2-AR. Thus the structure of such ligands appears to induce an arrestin-interacting form of the receptor only when bound to the β1-AR subtype.
- 27 July 2011
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 438 (1) , 191-202
Divergent agonist selectivity in activating β1- and β2-adrenoceptors for G-protein and arrestin coupling
The functional selectivity of adrenergic ligands for activation of β1- and β2-AR (adrenoceptor) subtypes has been extensively studied in cAMP signalling. Much less is known about ligand selectivity for arrestin-mediated signalling pathways. In the present study we used resonance energy transfer methods to compare the ability of β1- and β2-ARs to form a complex with the G-protein β-subunit or β-arrestin-2 in response to a variety of agonists with various degrees of efficacy. The profiles of β1-/β2-AR selectivity of the ligands for the two receptor–transducer interactions were sharply different. For G-protein coupling, the majority of ligands were more effective in activating the β2-AR, whereas for arrestin coupling the relationship was reversed. These data indicate that the β1-AR interacts more efficiently than β2-AR with arrestin, but less efficiently than β2-AR with G-protein. A group of ligands exhibited β1-AR-selective efficacy in driving the coupling to arrestin. Dobutamine, a member of this group, had 70% of the adrenaline (epinephrine) effect on arrestin via β1-AR, but acted as a competitive antagonist of adrenaline via β2-AR. Thus the structure of such ligands appears to induce an arrestin-interacting form of the receptor only when bound to the β1-AR subtype.
- 12 September 2005
- Published by Wiley in Journal of Neurochemistry
- Vol. 95 (4) , 1188-1200
Adenosine A2A receptors and metabotropic glutamate 5 receptors are co‐localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N‐methyl‐d‐aspartate effects
Hippocampal metabotropic glutamate 5 receptors (mGlu5Rs) regulate both physiological and pathological responses to glutamate. Because mGlu5R activation enhances NMDA‐mediated effects, and given the role played by NMDA receptors in synaptic plasticity and excitotoxicity, modulating mGlu5R may influence both the physiological and the pathological effects elicited by NMDA receptor stimulation. We evaluated whether adenosine A2A receptors (A2ARs) modulated mGlu5R‐dependent effects in the hippocampus, as they do in the striatum. Co‐application of the A2AR agonist CGS 21680 with the mGlu5R agonist (RS)‐2‐chloro‐s‐hydroxyphenylglycine(CHPG) synergistically reduced field excitatory postsynaptic potentials in the CA1 area of rat hippocampal slices. Endogenous tone at A2ARs seemed to be required to enable mGlu5R‐mediated effects, as the ability of CHPG to potentiate NMDA effects was antagonized by the selective A2AR antagonist ZM 241385 in rat hippocampal slices and cultured hippocampal neurons, and abolished in the hippocampus of A2AR knockout mice. Evidence for the interaction between A2ARs and mGlu5Rs was further strengthened by demonstrating their co‐localization in hippocampal synapses. This is the first evidence showing that hippocampal A2ARs and mGlu5Rs are co‐located and act synergistically, and that A2ARs play a permissive role in mGlu5R receptor‐mediated potentiation of NMDA effects in the hippocampus.
- 12 September 2005
- Published by Wiley in Journal of Neurochemistry
- Vol. 95 (4) , 1188-1200
Adenosine A2A receptors and metabotropic glutamate 5 receptors are co‐localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N‐methyl‐d‐aspartate effects
Hippocampal metabotropic glutamate 5 receptors (mGlu5Rs) regulate both physiological and pathological responses to glutamate. Because mGlu5R activation enhances NMDA‐mediated effects, and given the role played by NMDA receptors in synaptic plasticity and excitotoxicity, modulating mGlu5R may influence both the physiological and the pathological effects elicited by NMDA receptor stimulation. We evaluated whether adenosine A2A receptors (A2ARs) modulated mGlu5R‐dependent effects in the hippocampus, as they do in the striatum. Co‐application of the A2AR agonist CGS 21680 with the mGlu5R agonist (RS)‐2‐chloro‐s‐hydroxyphenylglycine(CHPG) synergistically reduced field excitatory postsynaptic potentials in the CA1 area of rat hippocampal slices. Endogenous tone at A2ARs seemed to be required to enable mGlu5R‐mediated effects, as the ability of CHPG to potentiate NMDA effects was antagonized by the selective A2AR antagonist ZM 241385 in rat hippocampal slices and cultured hippocampal neurons, and abolished in the hippocampus of A2AR knockout mice. Evidence for the interaction between A2ARs and mGlu5Rs was further strengthened by demonstrating their co‐localization in hippocampal synapses. This is the first evidence showing that hippocampal A2ARs and mGlu5Rs are co‐located and act synergistically, and that A2ARs play a permissive role in mGlu5R receptor‐mediated potentiation of NMDA effects in the hippocampus.
- 29 May 2003
- Published by Wiley in European Journal of Neuroscience
- Vol. 17 (10) , 2047-2055
Metabotropic glutamate receptor 5 (mGluR5)‐mediated phosphoinositide hydrolysis and NMDA‐potentiating effects are blunted in the striatum of aged rats: a possible additional mechanism in striatal senescence
The aim of the present work was to verify whether an impairment of subtype 5 metabotropic glutamate receptor‐mediated neurotransmission did occur in the aged striatum. To this end, the ability of the subtype 5 metabotropic glutamate receptor agonist, RS‐2‐chloro‐5‐hydroxyphenylglycine, to stimulate phosphoinositide hydrolysis and to potentiate N‐methyl‐d‐aspartate‐induced effects in striatal slices from young (3 months) and aged (24 months) rats was compared. The ability of RS‐2‐chloro‐5‐hydroxyphenylglycine to induce maximal phosphoinositide turnover and to potentiate N‐methyl‐d‐aspartate effects was significantly reduced in slices from old vs. young rats. These changes were associated with a significant reduction in the expression of subtype 5 metabotropic glutamate receptor protein (−28.8%) and phospholipase C‐β1 (−55.8%) in old striata, while receptor messenger ribonucleic acid expression was unchanged. These results show that the signalling associated with subtype 5 metabotropic glutamate receptors undergoes significant age‐related changes and that a reduced expression of subtype 5 metabotropic glutamate receptors and, more importantly, phospholipase C‐β1 may account for the functional decline of subtype 5 metabotropic glutamate receptors.
- 29 May 2003
- Published by Wiley in European Journal of Neuroscience
- Vol. 17 (10) , 2047-2055
Metabotropic glutamate receptor 5 (mGluR5)‐mediated phosphoinositide hydrolysis and NMDA‐potentiating effects are blunted in the striatum of aged rats: a possible additional mechanism in striatal senescence
The aim of the present work was to verify whether an impairment of subtype 5 metabotropic glutamate receptor‐mediated neurotransmission did occur in the aged striatum. To this end, the ability of the subtype 5 metabotropic glutamate receptor agonist, RS‐2‐chloro‐5‐hydroxyphenylglycine, to stimulate phosphoinositide hydrolysis and to potentiate N‐methyl‐d‐aspartate‐induced effects in striatal slices from young (3 months) and aged (24 months) rats was compared. The ability of RS‐2‐chloro‐5‐hydroxyphenylglycine to induce maximal phosphoinositide turnover and to potentiate N‐methyl‐d‐aspartate effects was significantly reduced in slices from old vs. young rats. These changes were associated with a significant reduction in the expression of subtype 5 metabotropic glutamate receptor protein (−28.8%) and phospholipase C‐β1 (−55.8%) in old striata, while receptor messenger ribonucleic acid expression was unchanged. These results show that the signalling associated with subtype 5 metabotropic glutamate receptors undergoes significant age‐related changes and that a reduced expression of subtype 5 metabotropic glutamate receptors and, more importantly, phospholipase C‐β1 may account for the functional decline of subtype 5 metabotropic glutamate receptors.
- Open Access
- 1 May 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (18) , 15778-15788
Promiscuous Coupling at Receptor-Gα Fusion Proteins
- 1 May 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (18) , 15778-15788
Open AccessPromiscuous Coupling at Receptor-Gα Fusion Proteins
- 1 February 1993
- Published by Elsevier in Virus Research
- Vol. 27 (2) , 119-131
Toscana virus genomic L segment: molecular cloning, coding strategy and amino acid sequence in comparison with other negative strand RNA viruses
- 1 February 1993
- Published by Elsevier in Virus Research
- Vol. 27 (2) , 119-131
Toscana virus genomic L segment: molecular cloning, coding strategy and amino acid sequence in comparison with other negative strand RNA viruses